Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child

Virus Research

Volumn 127, Issue 1, 2007, Pages 17-25

  Adu, Festus ^a   Iber, Jane ^b   Bukbuk, David ^c   Gumede, Nicksy ^d   Yang, Su Ju ^b   Jorba, Jaume ^b   Campagnoli, Ray ^b   Sule, Waidi Folorunso ^a   Yang, Chen Fu ^b   Burns, Cara ^b   Pallansch, Mark ^b   Harry, Tekena ^c   Kew, Olen ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c UNIVERSITY OF MAIDUGURI   (Nigeria)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Nigeria; Oral poliovaccine; Vaccine derived poliovirus; VDPV

Indexed keywords

NUCLEOTIDE; ORAL POLIOMYELITIS VACCINE; PROTEIN VP1;

AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CASE REPORT; CHILD; DNA FLANKING REGION; DNA SEQUENCE; ENTEROVIRUS; FLACCID PARALYSIS; HUMAN; IMMUNIZATION; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY; UNTRANSLATED REGION; VACCINE DERIVED POLIOVIRUS; VIRUS ATTENUATION; VIRUS CAPSID; VIRUS INFECTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS STRAIN;

5' UNTRANSLATED REGIONS; CAPSID PROTEINS; FECES; GENOME, VIRAL; HUMANS; INFANT; MALE; NIGERIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECOMBINATION, GENETIC; VACCINATION; VACCINES, SYNTHETIC;

ENTEROVIRUS; MIRIDAE; POLIOVIRUS;

EID: 34249021717     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.03.009     Document Type: Article

References (64)

1. Adu F.D., Iber J., Harry T., Burns C., Oyedele O., Adeniji J.A., Osei-Kwasi M., Kilpatrick D., Tomori O., and Kew O. Some genetic characteristics of Sabin-like poliovirus isolated from acute flaccid paralysis cases in Nigeria. Afr. J. Biotech. 2 (2003) 460-464
2. Alexander Jr. J.P., Gary Jr. H.E., and Pallansch M.A. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175 Suppl. 1 (1997) S176-S182
3. Arita M., Zhu S.L., Yoshida H., Yoneyama T., Miyamura T., and Shimizu H. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 79 (2005) 12650-12657
4. Bellmunt A., May G., Zell R., Pring-Akerblom P., Verhagen W., and Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265 (1999) 178-184
5. Blomqvist S., Savolainen C., Laine P., Hirttio P., Lamminsalo E., Penttila E., Joks S., Roivainen M., and Hovi T. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78 (2004) 4876-4883
6. Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., Soresina A.R., Vivarelli R., Delpeyroux F., Martín J., and Fiore L. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 84 (2003) 1215-1221
7. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005. Morbid. Mortal. Wkly. Rep. 54 (2005) 958-961
8. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2004-July 2005. Morbid. Mortal. Wkly. Rep. 54 (2005) 873-877
9. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission-worldwide, January 2005-March 2006. Morbid. Mortal. Wkly. Rep. 55 (2006) 458-462
10. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005. Morbid. Mortal. Wkly. Rep. 55 (2006) 145-150
11. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, 2005-2006. Morbid. Mortal. Wkly. Rep. 56 (2007) 278-281
12. Cherkasova E.A., Korotkova E.A., Yakovenko M.L., Ivanova O.E., Eremeeva T.P., Chumakov K.M., and Agol V.I. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76 (2002) 6791-6799
13. Ehrenfeld E., and Teterina N.L. Initiation of translation of picornavirus RNAs: structure and function of the internal ribosome entry site. In: Semler B.L., and Wimmer E. (Eds). Molecular Biology of Picornaviruses (2002), ASM Press, Washington, D.C. 159-169
14. Felsenstein J. Evolutionary trees from DNA sequences: a maximum likelihood approach. J. Mol. Evol. 17 (1981) 368-376
15. Felsenstein, J., 2002. University of Washington, Department of Genetics. PHYLIP (phylogeny inference package), version 3.6.
16. Georgescu M.M., Balanant J., Macadam A., Otelea D., Combiescu M., Aubert-Combiescu A., Crainic R., and Delpeyroux F. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 71 (1997) 7758-7768
17. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenia M.A., da Silva E., Khan A.J., Webster A.D.B., Minor P.D., Dunn G., Asturias E., Hussain H., Pallansch M.A., Kew O.M., Winkelstein J., Sutter R., and Polio Project Team. Search for poliovirus carriers in persons with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. WHO 82 (2004) 3-8
18. Hovi T., and Stenvik M. Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene. J. Clin. Microbiol. 32 (1994) 1366-1368
19. Kew O.M., Sutter R.W., Nottay B., McDonough M., Prevots D.R., Quick L., and Pallansch M. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36 (1998) 2893-2899
20. Kew O.M., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., André J., Blackman E., Freeman C.J., Jorba J., Sutter R., Tambini G., Venczel L., Pedreira C., Laender F., Shimizu H., Yoneyama T., Miyamura T., van der Avoort H., Oberste M.S., Kilpatrick D., Cochi S., Pallansch M., and de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296 (2002) 356-359
21. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., and Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59 (2005) 587-635
22. Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., and Sutter R.W. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188 (2003) 1845-1852
23. Kilpatrick D.R., Nottay B., Yang C.-F., Yang S.-J., Mulders M.N., Holloway B.P., Pallansch M.A., and Kew O.M. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 34 (1996) 2990-2996
24. Kilpatrick D.R., Nottay B., Yang C.-F., Yang S.-J., da Silva E., Peñaranda S., Pallansch M., and Kew O. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 36 (1998) 352-357
25. Kilpatrick D.R., Ching K., Iber J., Campagnoli R., Freeman C.J., Mishrik N., Pallansch M.A., and Kew O.M. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J. Clin. Microbiol. 42 (2004) 4313-4315
26. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16 (1980) 111-120
27. Korotkova E.A., Park R., Cherkasova E.A., Lipskaya G.Y., Chumakov K.M., Feldman E., Kew O.M., and Agol V.I. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J. Virol. 77 (2003) 12460-12465
28. Kumar S., Tamura K., and Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5 (2004) 150-163
29. La Monica N., Meriam C., and Racaniello V.R. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J. Virol. 57 (1986) 515-525
30. Lentz K.N., Smith A.D., Geisler S.C., Cox S., Buontempo P., Skelton A., DeMartino J., Rozhon E., Schwartz J., Girijavallabhan V., O'Connell J., and Arnold E. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5 (1997) 961-978
31. Liang X., Zhang Y., Xu W., Wen N., Zou S., Lee L.A., and Yu J. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J. Infect. Dis. 194 (2006) 545-551
32. Liu H.-M., Zheng D.-P., Zhang L.-B., Oberste M.S., Pallansch M.A., and Kew O.M. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J. Virol. 74 (2000) 11153-11161
33. Liu H.-M., Zheng D.-P., Zhang L.-B., Oberste M.S., Kew O.M., and Pallansch M.A. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J. Virol. 77 (2003) 10994-11005
34. Macadam A.J., Pollard S.R., Ferguson G., Skuce R., Wood D., Almond J.W., and Minor P.D. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192 (1993) 18-26
35. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martín J., O'Leary P., Thompson R.A., Osman H., Wood P., Minor P., Wood D.J., and Pillay D. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363 (2004) 1509-1513
36. Martín J., Dunn G., Hull R., Patel V., and Minor P.D. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74 (2000) 3001-3010
37. Martín J., Odoom K., Tuite G., Dunn G., Hopewell N., Cooper G., Fitzharris C., Butler K., Hall W.W., and Minor P.D. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78 (2004) 13839-13847
38. Minor P.D. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161 (1990) 121-154
39. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. 105 (2001) 75-80
40. Minor P.D., and Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J. Gen. Virol. 69 (1988) 1091-1096
41. Olsen G.J., Matsuda H., Hagstrom R., and Overbeek R. fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood. Comput. Appl. Biosci. 10 (1994) 41-48
42. Pipkin P.A., Wood D.J., Racaniello V.R., and Minor P.D. Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J. Virol. Methods 41 (1993) 333-340
43. Posada D., and Crandall K.A. MODELTEST: testing the model of DNA substitution. Bioinformatics 14 (1998) 817-818
44. Ren R., Moss E.G., and Racaniello V.R. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65 (1991) 1377-1382
45. Rousset D., Rakoto-Andrianarivelo M., Razafindratsimandresy R., Randriamanalina B., Guillot S., Balanant J., Mauclère P., and Delpeyroux F. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9 (2003) 885-887
46. Sabin A.B. Recent Studies and Field Tests with a Live Attenuated Poliovirus Vaccine. Live Poliovirus Vaccines. Papers Presented and Discussions Held at the First International Conference on Live Poliovirus Vaccines (1959), Pan American Sanitary Bureau, Washington, D.C. 14-33
47. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
48. Shimizu H., Thorley B., Paladin F.J., Brussen K.A., Stambos V., Yuen L., Utama A., Tano Y., Arita M., Yoshida H., Yoneyama T., Benegas A., Roesel S., Pallansch M., Kew O., and Miyamura T. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 78 (2004) 13512-13521
49. Shulman L., Manor J., Handsher R., Delpeyroux F., McDonough M., Halmut T., Silberstein I., Alfandari J., Quay J., Fisher T., Robinov J., Kew O., Crainic R., and Mendelson E. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38 (2000) 3729-3734
50. Sutter R.W., Kew O.M., and Cochi S.L. Poliovirus vaccine-live. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. fourth ed. (2004), W.B. Saunders Company, Philadelphia 651-705
51. Toyoda H.M., Kohara M., Kataoka Y., Suganuma T., Omata T., Imura N., and Nomoto A. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174 (1984) 561-585
52. van der Avoort H.G.A.M., Hull B.P., Hovi T., Pallansch M.A., Kew O.M., Crainic R., Wood D.J., Mulders M.N., and van Loon A.M. A comparative study of five methods of intratypic differentiation of polioviruses. J. Clin. Microbiol. 33 (1995) 2562-2566
53. World Health Organization. Field Guide for Supplementary Activities Aimed at Achieving Polio Eradication, 1996 revision, WHO/EPI/GEN/95.01 Rev.1 (1997), World Health Organization, Geneva, Switzerland 153 pp
54. World Health Organization. Transmission of wild poliovirus type 2-apparent global interruption. Wkly. Epidemiol. Rec. 76 (2001) 95-97
55. World Health Organization. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Wkly. Epidemiol. Rec. 79 (2004) 393-398
56. World Health Organization. Polio Laboratory Manual. fourth ed. (2004), World Health Organization, Geneva
57. World Health Organization. Progress towards global poliomyelitis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly. Epidemiol. Rec. 79 (2004) 349-356
58. Yakovenko M.L., Cherkasova E.A., Rezapkin G.V., Ivanova O.E., Ivanov A.P., Eremeeva T.P., Baykova O.Y., Chumakov K.M., and Agol V.I. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80 (2006) 2641-2653
59. Yang C.-F., De L., Holloway B.P., Pallansch M.A., and Kew O.M. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res. 20 (1991) 159-179
60. Yang C.-F., Naguib T., Yang S.-J., Nasr E., Jorba J., Ahmed N., Campagnoli R., van der Avoort H., Shimizu H., Yoneyama T., Miyamura T., Pallansch M.A., and Kew O. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. J. Virol. 77 (2003) 8366-8377
61. Yang C.-F., Chen H.-Y., Jorba J., Sun H.-C., Yang S.-J., Lee H.-C., Huang Y.-C., Lin T.-Y., Chen P.-J., Shimizu H., Nishimura Y., Utama A., Pallansch M., Miyamura T., Kew O., and Yang J.-Y. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79 (2005) 12623-12634
62. Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput. Appl. Biosci. 13 (1997) 555-556
63. Yang Z., and Nielsen R. Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models. Mol. Biol. Evol. 17 (2000) 32-43
64. Yoshida H., Horie H., Matsuura K., Kitamura T., Hashizume S., and Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J. Gen. Virol. 83 (2002) 1101-1107